Castle Biosciences (NASDAQ: CSTL) saw its stock price surge 5.48% in Monday's trading session after the company reported better-than-expected third-quarter revenue. The molecular diagnostics company, which focuses on skin cancers and other dermatologic diseases, delivered a significant top-line beat that caught investors' attention.

According to the company's earnings release, Castle Biosciences reported Q3 revenue of $83.043 million, handily surpassing the IBES estimate of $71.2 million. This substantial revenue outperformance, beating analyst expectations by nearly $12 million, was the primary driver behind the stock's impressive rally.

While the company's top-line growth impressed, Castle Biosciences still faced challenges on the bottom line. The company reported a pre-tax loss of $386,000 for the quarter, indicating that profitability remains a work in progress. However, investors appeared to focus more on the strong revenue growth, potentially seeing it as a sign of increasing market adoption for Castle's diagnostic tests.